Masimo Corporation (MASI) - Stock Analysis
Last updated: Mar 8, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Definitive $180 cash takeover by Danaher announced 2026-02-17 created a large premium and sharp momentum; stock trades below the deal price with near-term catalysts (2/26 earnings call, evolving shareholder litigation) driving an attractive event-arbitrage spread over the next few days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross margins ⢠Large operating costs ⢠Leverage & valuation MASI shows durable high gross margins and strong free cash flow with a recent profitable quarter, but heavy operating costs, meaningful leverage and rich multiples leave fullâyear returns negative and valuation stretched.
Price Behavior
Key Price Behavior Insights: ⢠Strong uptrend ⢠Stalled at resistance ⢠MidâFebruary jump Support Level: $135â$140 Resistance Level: $175â$176 Over the last month MASI rallied roughly 30% from about $135 to $175 and trades above its 21âday SMA (bullish momentum) but has stalled at nearâterm resistance around $175â176 and shows an unexplained midâFebruary jump that may inflate shortâterm volatility.
Sentiment & News
Key News Insights: ⢠Deal premium ⢠Share spike ⢠Legal scrutiny Danaher agreed to acquire Masimo for $180/share (~$9.9B), driving a ~34% jump on unanimous board approval but triggering legal challenges and heightened scrutiny ahead of Masimo's FY2025 results.
AI Summary
Masimo is now a dealâdriven merger arbitrage where upside is largely capped by Danaher's $180 allâcash offer, so investors should treat it as an eventâdriven play rather than a pure growth equity; the key risk is deal execution (litigation/regulatory timing) which will dominate returns. Actionable: monitor legal filings, regulator signals, and the arbitrage spreadâonly take/maintain positions if the spread adequately compensates for likely delays and litigation risk, otherwise reprice exposure to the company's standalone fundamentals if the deal falters.
Description
Masimo designs and manufactures noninvasive physiological monitoring devices and hospital automation software sold worldwide. Its clinical product set includes advanced pulse oximetry that addresses motion and low-perfusion limits of conventional oximeters, a multi-parameter platform for hemoglobin species and oxygen-related metrics, EEG-based brain function monitoring, capnography and gas analyzers, regional oximetry and hemodynamic tools, as well as connectivity and hospital surveillance solutions. The company sells through direct sales, distributors and OEM partners to hospitals, emergency and home care providers, long-term care facilities, physician offices, veterinarians and consumers; it was founded in 1989 and is headquartered in Irvine, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 19 | Feb 26 | MASI | Masimo Corporation | Definitive $180 cash takeover by Danaher announced 2026-02-17 created a large premium and sharp momentum; stock trades below the deal price with near-term catalysts (2/26 earnings call, evolving shareholder litigation) driving an attractive event-arbitrage spread over the next few days. | Closed | -0.1% |
| Nov 17 | Nov 24 | MASI | Masimo Corporation | Q3 2025 earnings beat with strong margin expansion, increased free cash flow, positive patent infringement ruling, extended FDA clearances, and constructive technical trends near moving averages underpin Masimo as a near-term growth opportunity. | Closed | -1.0% |